JP2013520986A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520986A5 JP2013520986A5 JP2012555542A JP2012555542A JP2013520986A5 JP 2013520986 A5 JP2013520986 A5 JP 2013520986A5 JP 2012555542 A JP2012555542 A JP 2012555542A JP 2012555542 A JP2012555542 A JP 2012555542A JP 2013520986 A5 JP2013520986 A5 JP 2013520986A5
- Authority
- JP
- Japan
- Prior art keywords
- galactosidase
- multimeric protein
- protein structure
- activity
- exposed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 57
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 57
- 102000004169 proteins and genes Human genes 0.000 claims 45
- 108090000623 proteins and genes Proteins 0.000 claims 45
- 230000000694 effects Effects 0.000 claims 30
- 230000002132 lysosomal effect Effects 0.000 claims 14
- 230000007423 decrease Effects 0.000 claims 8
- 239000000178 monomer Substances 0.000 claims 8
- 239000007864 aqueous solution Substances 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003431 cross linking reagent Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- -1 poly (alkylene glycol Chemical compound 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 125000005309 thioalkoxy group Chemical group 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30948710P | 2010-03-02 | 2010-03-02 | |
| US61/309,487 | 2010-03-02 | ||
| PCT/IL2010/000956 WO2011061736A1 (en) | 2009-11-17 | 2010-11-17 | Alkaline alpha galactosidase for the treatment of fabry disease |
| ILPCT/IL2010/000956 | 2010-11-17 | ||
| US201161434499P | 2011-01-20 | 2011-01-20 | |
| US201161434503P | 2011-01-20 | 2011-01-20 | |
| US61/434,499 | 2011-01-20 | ||
| US61/434,503 | 2011-01-20 | ||
| PCT/IL2011/000209 WO2011107990A1 (en) | 2010-03-02 | 2011-03-02 | Stabilized alpha-galactosidase and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014160449A Division JP5871999B2 (ja) | 2010-03-02 | 2014-08-06 | 安定化α−ガラクトシダーゼおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013520986A JP2013520986A (ja) | 2013-06-10 |
| JP2013520986A5 true JP2013520986A5 (enExample) | 2014-04-17 |
| JP5758920B2 JP5758920B2 (ja) | 2015-08-05 |
Family
ID=44121635
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012555542A Active JP5758920B2 (ja) | 2010-03-02 | 2011-03-02 | 安定化α−ガラクトシダーゼおよびその使用 |
| JP2014160449A Active JP5871999B2 (ja) | 2010-03-02 | 2014-08-06 | 安定化α−ガラクトシダーゼおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014160449A Active JP5871999B2 (ja) | 2010-03-02 | 2014-08-06 | 安定化α−ガラクトシダーゼおよびその使用 |
Country Status (23)
| Country | Link |
|---|---|
| EP (3) | EP2542675B1 (enExample) |
| JP (2) | JP5758920B2 (enExample) |
| KR (1) | KR101928403B1 (enExample) |
| CN (1) | CN102933707B (enExample) |
| AU (1) | AU2011222452B2 (enExample) |
| BR (1) | BR112012022029B1 (enExample) |
| CA (1) | CA2791461C (enExample) |
| DK (1) | DK2865751T3 (enExample) |
| ES (2) | ES2708843T3 (enExample) |
| FI (1) | FIC20230032I1 (enExample) |
| FR (1) | FR23C1041I2 (enExample) |
| HR (1) | HRP20200428T1 (enExample) |
| HU (2) | HUE030959T2 (enExample) |
| IL (2) | IL221741A (enExample) |
| IN (1) | IN2012MN02262A (enExample) |
| NL (1) | NL301249I2 (enExample) |
| NO (1) | NO2023041I1 (enExample) |
| NZ (2) | NZ623294A (enExample) |
| PL (1) | PL2865751T3 (enExample) |
| SG (2) | SG183558A1 (enExample) |
| SI (1) | SI2865751T1 (enExample) |
| WO (1) | WO2011107990A1 (enExample) |
| ZA (1) | ZA201206725B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| RS60129B1 (sr) * | 2011-01-20 | 2020-05-29 | Protalix Ltd | Kompozicije alfa-galaktozidaze |
| TWI642782B (zh) * | 2013-10-23 | 2018-12-01 | 健臻公司 | 重組醣蛋白及其用途 |
| US20170360900A1 (en) | 2014-12-22 | 2017-12-21 | Codexis, Inc. | Human alpha-galactosidase variants |
| WO2016116966A1 (en) * | 2015-01-22 | 2016-07-28 | Jcr Pharmaceuticals Co., Ltd. | Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins |
| CN107429257B (zh) | 2015-03-17 | 2022-02-15 | 艾丽法有限责任公司 | 糖基化溶酶体蛋白、生产方法和用途 |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| CA3048151A1 (en) * | 2017-01-05 | 2018-07-12 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| CN110651043A (zh) * | 2017-06-07 | 2020-01-03 | 天野酶制品株式会社 | 乳糖酶原料粉末和乳糖酶制剂 |
| MX2021007552A (es) | 2018-12-20 | 2021-08-11 | Codexis Inc | Variantes de alfa-galactosidasa humana. |
| IL295818A (en) * | 2020-02-28 | 2022-10-01 | Codexis Inc | Human alpha-galactosidase variants |
| CN117098559A (zh) | 2020-11-03 | 2023-11-21 | 波塔力克斯有限公司 | 修饰的尿酸酶及其用途 |
| CN112176026A (zh) * | 2020-11-06 | 2021-01-05 | 诺道中科(北京)生物科技有限公司 | 一种α-半乳糖苷酶活性的检测试剂盒 |
| CN116254287B (zh) * | 2022-11-24 | 2024-06-04 | 西北农林科技大学 | 玉米ZmAGA3基因用于提高植物耐旱性的应用 |
| CN118243646B (zh) * | 2024-04-24 | 2025-01-24 | 武汉简为医疗科技有限公司 | 一种乳糖不耐受检测试剂盒及其使用方法 |
| JP7745040B1 (ja) | 2024-06-21 | 2025-09-26 | デンカ株式会社 | 目的タンパク質の回収方法及び製造方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US5401650A (en) * | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| CA2052728A1 (en) | 1991-10-03 | 1993-04-04 | Guy Ampleman | Glycidyl azide polymer |
| US6329191B1 (en) * | 1993-08-30 | 2001-12-11 | Hawaii Biotechnology Group, Inc. | DNA encoding recombinant coffee bean alpha-galactosidase |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US20050032211A1 (en) * | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
| WO1999012959A1 (en) * | 1997-09-05 | 1999-03-18 | Altus Biologics Inc. | Carbohydrate crosslinked glycoprotein crystals |
| IL125423A (en) | 1998-07-20 | 2004-08-31 | Israel State | Alkaline alpha-galactosidase having broad substrate specificity |
| WO2000059926A1 (en) | 1999-04-02 | 2000-10-12 | Ajinomoto Co., Inc. | Process for producing subunit peptide origintaing in polymer protein |
| EP1523548B1 (en) | 2002-05-15 | 2009-12-30 | Agricultural Research Organization | Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same |
| US7951557B2 (en) | 2003-04-27 | 2011-05-31 | Protalix Ltd. | Human lysosomal proteins from plant cell culture |
| WO2006108052A2 (en) * | 2005-04-06 | 2006-10-12 | Genzyme Corporation | Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting |
| US7935336B2 (en) * | 2005-11-18 | 2011-05-03 | Tokyo Metropolitan Organization For Medical Research | Highly functional enzyme having α-galactosidase activity |
| US20100144008A1 (en) | 2006-12-21 | 2010-06-10 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Treatment of fabry disease |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP1955712A1 (en) * | 2007-02-09 | 2008-08-13 | Scil proteins GmbH | Multimeric conjugate |
| EP2192924B1 (en) * | 2007-08-20 | 2017-10-11 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
-
2011
- 2011-03-02 DK DK14195875.1T patent/DK2865751T3/en active
- 2011-03-02 WO PCT/IL2011/000209 patent/WO2011107990A1/en not_active Ceased
- 2011-03-02 NZ NZ623294A patent/NZ623294A/en unknown
- 2011-03-02 JP JP2012555542A patent/JP5758920B2/ja active Active
- 2011-03-02 HU HUE14195875A patent/HUE030959T2/en unknown
- 2011-03-02 ES ES16173953T patent/ES2708843T3/es active Active
- 2011-03-02 CN CN201180022145.6A patent/CN102933707B/zh active Active
- 2011-03-02 SG SG2012064580A patent/SG183558A1/en unknown
- 2011-03-02 BR BR112012022029-2A patent/BR112012022029B1/pt active IP Right Grant
- 2011-03-02 CA CA2791461A patent/CA2791461C/en active Active
- 2011-03-02 ES ES14195875.1T patent/ES2606532T3/es active Active
- 2011-03-02 EP EP11712340.6A patent/EP2542675B1/en active Active
- 2011-03-02 IN IN2262MUN2012 patent/IN2012MN02262A/en unknown
- 2011-03-02 NZ NZ602317A patent/NZ602317A/en unknown
- 2011-03-02 EP EP16173953.7A patent/EP3088514B1/en active Active
- 2011-03-02 PL PL14195875T patent/PL2865751T3/pl unknown
- 2011-03-02 SG SG10201502609QA patent/SG10201502609QA/en unknown
- 2011-03-02 KR KR1020127025725A patent/KR101928403B1/ko active Active
- 2011-03-02 SI SI201131048A patent/SI2865751T1/sl unknown
- 2011-03-02 AU AU2011222452A patent/AU2011222452B2/en active Active
- 2011-03-02 EP EP14195875.1A patent/EP2865751B1/en active Active
-
2012
- 2012-09-02 IL IL221741A patent/IL221741A/en active IP Right Grant
- 2012-09-07 ZA ZA2012/06725A patent/ZA201206725B/en unknown
-
2014
- 2014-08-06 JP JP2014160449A patent/JP5871999B2/ja active Active
-
2017
- 2017-06-29 IL IL253249A patent/IL253249B/en active IP Right Grant
-
2020
- 2020-03-16 HR HRP20200428TT patent/HRP20200428T1/hr unknown
-
2023
- 2023-10-31 HU HUS2300038C patent/HUS2300038I1/hu unknown
- 2023-11-01 NO NO2023041C patent/NO2023041I1/no unknown
- 2023-11-01 NL NL301249C patent/NL301249I2/nl unknown
- 2023-11-02 FR FR23C1041C patent/FR23C1041I2/fr active Active
- 2023-11-02 FI FIC20230032C patent/FIC20230032I1/fi unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10828398B2 (en) | Functionalized zwitterionic and mixed charge polymers, related hydrogels, and methods for their use | |
| CN104395391B (zh) | 双重衍生化的壳聚糖纳米粒子以及制造和使用其用于体内基因转移的方法 | |
| US20150165058A1 (en) | Membrane lytic poly(amido amine) polymers for the delivery of oligonucleotides | |
| AU2014306021B2 (en) | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | |
| US20100144035A1 (en) | Delivery system for nucleic acids using cationic polymer conjugates | |
| CN100393778C (zh) | 具有磷酰胆碱基的聚硅氧烷及其制造方法 | |
| JP6913144B2 (ja) | 二重誘導体化キトサンナノ粒子、並びに生体内での遺伝子導入のためのその製造、及び使用方法 | |
| JP2014516993A5 (enExample) | ||
| JP2020527382A (ja) | Ｎ−オキシド及びエクトインモノマー、ポリマー、それらの組成物及び関連方法 | |
| BR112012022029A2 (pt) | estrutura de proteina multimérica composto farmaceutico método pasra tratamento da doença de fabry e processo pqara preparação da estrutura de proteína multimérica | |
| JP5406281B2 (ja) | 多糖類誘導体およびそのハイドロゲル | |
| CN107596380B (zh) | 基于聚乙二醇-聚碳酸酯的还原敏感性喜树碱前药及其制备方法和应用 | |
| CN105821005A (zh) | 用于处理病毒的阳离子型聚胺 | |
| KR101041985B1 (ko) | 핵산 전달용 고분자의 제조방법 및 상기 고분자를 함유하는 핵산 전달용 조성물 | |
| CN100494223C (zh) | 季胺盐改性的壳聚糖亲核no供体的合成方法 | |
| CN112979942B (zh) | 侧基可功能化的聚氨基酸嵌段聚合物、其制备方法及响应型可逆粘附性可注射水凝胶 | |
| US11890347B2 (en) | PH-responsive polymer and drug delivery system | |
| CN102675626B (zh) | 含三氮唑的聚乙二醇蛋白质修饰剂及其制备方法和应用 | |
| KR20200138336A (ko) | 분해성 폴리에틸렌글리콜 유도체 | |
| KR20190002861A (ko) | 히알루론산 기반 보습 소재 | |
| JP2021055079A (ja) | マルチアーム型分解性ポリエチレングリコール誘導体 | |
| WO2018151258A1 (ja) | 薬物送達用担体及び薬物送達システム | |
| CN102786682B (zh) | 聚乙二醇醛基活性物 | |
| KR20250044925A (ko) | 겔 형성용 재료 및 겔 조성물 | |
| US10881682B2 (en) | Therapeutic compositions comprising n-alkyl-hydroxy polymers |